Recurrent Breast Cancer Terminated Phase 2 Trials for Trastuzumab (DB00072)

Also known as: Breast Cancer Recurrent / Breast cancer NOS recurrent / Carcinoma breast recurrent / Breast carcinoma recurrent / Breast carcinoma NOS recurrent

IndicationStatusPhase
DBCOND0028640 (Recurrent Breast Cancer)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00079326Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast CancerTreatment